Hyperthermia Newsletter - March 2017
Dr. Sennewald
Radiated Hyperthermia the Superior Method

A new report published in the International Journal of Hyperthermia proves that radiated hyperthermia is superior to capacitive hyperthermia in the treatment of superficial cancerous tumors.

In a recent study at the Department of Radiation Oncology of the AMC Academisch Medisch Centrum Amsterdam, H.P. Kok and J. Crezee compared radiated and capacitive hyperthermia to determine which technique offers the more effective heating characteristics, for example, in the treatment of recurrent and metastatic malignant melanoma and recurrent breast cancer. Using their in-house treatment planning software, the Dutch researchers computed the heat delivery in terms of the specific absorption rate (SAR) during patient simulations carried out on a perfused muscle-equivalent phantom and phantoms with a superficial fat layer. Subsequently, they examined a real patient model with a breast cancer recurrence, with the target assumed to have muscle-like properties, fat properties or heterogeneous properties in each case.

The report, published in January, shows that capacitive heating techniques have difficulty passing through the fat layer, often resulting in hot spots that cause patient discomfort and prevent the tumor from reaching the therapeutic temperature. Radiative heating typically avoids these disadvantages, since the power absorption in the poorly-perfused fat tissue is much lower than in muscle tissue, which produces the higher target temperatures necessary for a therapeutic effect.

Overall, Drs. Kok and Crezee observed that radiative hyperthermia yields a temperature in at least 90% of the target volume that is 0.4–1.1 °C higher compared to capacitive heating. This corresponds approximately to a factor 2–4 difference in the thermal dose.

As a result of the higher tumor temperatures that can be achieved, the two researchers concluded that radiative heating will benefit the clinical outcome.

Read the entire report:
Overall efficacy confirmed for locoregional recurrent breast cancer

A meta-analysis of 34 studies revealed that the overall complete response rate for locoregional recurrent breast cancer (LRBC) increases by 22% after adding hyperthermia to radiotherapy. Last April, Prof. Niloy Datta of Aarau Cantonal Hospital in Switzerland, reported on a systematic review of the results of 34 studies, totaling 2110 patients, to evaluate the treatment outcomes of LRBCs combining radiation therapy and hyperthermia.
The article in the International Journal of Radiation Oncology shows that thermoradiation therapy enhances the likelihood of complete response rates in LRBCs over radiotherapy alone from 38.1% to 60.2%, with minimal acute and late morbidities. Moreover, in those patients who were reirradiated with the addition of hyperthermia, 66.6% achieved a complete response without any additional significant treatment morbidity. Prof. Datta thus concluded that thermoradiation therapy can be considered as an effective and safe treatment option in LRBCs.
Datta, Niloy R. et al. Hyperthermia and Radiation Therapy in Locoregional Recurrent Breast Cancers: A Systematic Review and Meta-analysis. Int J Radiation Oncol Biol Phys 2016;94:1073–1087
Dr. Sennewald Medizintechnik GmbH

Dr. Sennewald Medizintechnik GmbH was founded in 1985 by Dr. Gerhard Sennewald in Munich with the goal of discovering trendsetting electro-medical systems providing innovative and beneficial medical treatments and introducing them in Europe. From the beginning, cancer therapy was at the forefront of the company, with a focus on regional and local hyperthermia.

Martin Wadepohl,
Manager International Sales

Dirk Lutter, Sales Manager

Monica Sennewald, Marketing Director

Dr. Gerhard Sennewald, CEO
Copyright © 2017 Dr. Sennewald Medizintechnik GmbH, All rights reserved.

Fon: +49 (0)89 542143-20
Mobile: +49 (0)172 9111479
Fax: +49 (0)89 542143-30
EFAX:    +49 (0)89 95464138

Geschäftsführer: Dr. Dipl.-Ing. Gerhard W. Sennewald
Handelsregister: Amtsgericht München HRB 75654
USt-IdNr.: DE 129331634
WEEE-Reg.-Nr.: DE 22905506